Table 1 Clinico-pathological characteristics of the Reactive Lymphoid Hyperplasia (RLH) analysed in the study
From: Identification of stromal proteins overexpressed in nodular sclerosis Hodgkin lymphoma
Intensity of immunostaining | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
n° | age | sex | size (cm) | Localisation | subtype | CD30 | CD15 | EBV | Versican | Fibulin-1 | Periostin |
RLH1 | 47 | F | 0,7 | inguinal | benign lymph node | / | / | / | - | -/+ | -/+ |
RLH2 | 68 | M | 1,3 | inguinal | benign lymph node | / | / | / | - | -/+ | + |
RLH3 | 87 | M | 0,9 | internal mammary chain | benign lymph node | - | / | / | - | - | -/+ |
RLH4 | 59 | M | 2 | axillary | follicular hyperplasia | +/- | - | - | - | -/+ | -/+* |
RLH5 | 38 | M | 1,3 | cervical | follicular hyperplasia | / | / | / | - | - | -/+ |
RLH6 | 24 | M | 1,8 | axillary | follicular hyperplasia | +/- | / | - | - | - | + |
RLH7 | 62 | F | 0,7 | axillary | follicular hyperplasia | / | / | / | - | - | + |
RLH8 | 22 | M | 1,2 | spinal | follicular hyperplasia | / | / | / | - | - | + |
RLH9 | 22 | M | 1,9 | submaxillary | mixed lymphoid hyperplasia | - | - | / | - | -/+ | - |
RLH10 | 28 | M | 1,9 | cervical | mixed lymphoid hyperplasia | / | / | - | + | -/+ | ++ |
RLH11 | 46 | F | 1,7 | inguinal | mixed lymphoid hyperplasia | - | / | - | -/+ | -/+ | ++ |
RLH12 | 38 | F | 1,3 | subdigastric | mixed lymphoid hyperplasia | / | / | / | - | + | ++ |
RLH13 | 39 | F | 0,9 | supraclavicular | mixed lymphoid hyperplasia | +/- | / | / | -/+ | -/+ | ++ |
RLH14 | 24 | F | 0,5 | cervical | sarcoidosis | / | / | / | - | -/+ | + |
RLH15 | 57 | M | 1,5 | mediastinal | sarcoidosis | / | / | / | - | - | + |